Oncotarget

Oncotarget
DisciplineOncology
LanguageEnglish
Edited byMikhail Blagosklonny, Andrei V. Gudkov
Publication details
History2010–present
Publisher
FrequencyContinuous Publication
Yes
LicenseCreative Commons Attribution 3.0 License
Standard abbreviations
ISO 4Oncotarget
Indexing
ISSN1949-2553
OCLC no.408119940
Links

Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. The journal was established in 2010 and is published by Impact Journals. The editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov.

Abstracting and indexing

The journal is abstracted and indexed in Index Medicus/MEDLINE/PubMed[1] and Scopus.[2] In 2022, it was re-indexed by Index Medicus/MEDLINE[3] after being dropped in 2017.[4][5][1] In 2018 Clarivate delisted the journal from the Journal Citation Reports and all of its other products because "the journal no longer meets the standards necessary for continued coverage", despite having listed the journal as a "Rising Star from Essential Science Indicators"[6] only a few months prior.[7]

Reception

The peer review process employed by the journal has been criticized by Jeffrey Beall,[8] a university librarian and expert on predatory open access publishing, who also included the journal on his list of "potential, possible, or probable predatory scholarly open-access journals" in July 2015.[8][9] Allegedly, journal editor Mikhail Blagosklonny responded by threatening to retract the papers of Beall's colleagues at the University of Colorado.[4][5]

References

  1. ^ a b "Oncotarget". NLM Catalog. National Center for Biotechnology Information. Retrieved 2016-04-19.
  2. ^ "Source details: Oncotarget". Scopus preview. Elsevier. Retrieved 2018-01-27.
  3. ^ "Journals Recently Accepted for Inclusion in MEDLINE". www.nlm.nih.gov. Retrieved 2023-01-06.
  4. ^ a b "Widely used U.S. government database delists cancer journal". Retraction Watch. October 25, 2017. Retrieved October 25, 2017.
  5. ^ a b Zimmer, Katarina (October 26, 2017). "Oncotarget Journal Cut from Medline". The Scientist.
  6. ^ "Rising Stars from Essential Science Indicators". Clarivate Analytics. 2017-10-18. Retrieved 2018-01-21.
  7. ^ "Indexing company praises cancer journal, then kicks it out". Retraction Watch. 2018-01-19. Retrieved 2018-01-20.
  8. ^ a b Beall, Jeffrey (19 April 2016). "Oncotarget's Peer Review is Highly Questionable". Scholarly Open Access. WordPress.com. Archived from the original on 20 April 2016. Retrieved 19 April 2016.
    "Oncotarget's Peer Review is Highly Questionable (Jeffrey Beall". KSCIEN (Reprint of Beall's blog post). Retrieved 27 Dec 2019.
  9. ^ Beall, Jeffrey (16 April 2016). "LIST OF STANDALONE JOURNALS: Potential, possible, or probable predatory scholarly open-access journals". Scholarly Open Access. WordPress.com. Archived from the original on 2 December 2016. Retrieved 19 April 2016.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.